Company
Every investor coverage indicates participated in a round Exiqon A/S raised.
Companies Exiqon A/S acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
| Name | Role | Sources |
|---|---|---|
| Dr Henrik Ørum | Founder | Brandon Capital portfolio, Brandon BioCatalyst portfolio |
Stories naming Exiqon A/S. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Cancer biotech Amaroq Therapeutics appointed four experts to its advisory board as it moves toward clinical trials; the New Zealand company's backers include Brandon Capital, which reports $14m invested to date.
New Zealand biotech Amaroq Therapeutics reported early progress toward clinical trials and appointed four leading scientists to its scientific advisory board, strengthening its lncRNA cancer therapy programme.